SLS SELLAS Life Sciences Group, Inc. Insider Trading

Director Kalin Katherine Bach purchases 63.4K shares of SLS at $1.59, more than doubling her stake to 104.4K shares, amid -30.1% 52-week underperformance.

Director Kalin Katherine Bach acquired 63,400 shares at $1.59 on 2025-11-19, increasing her holdings by 154.6% to 104,400 shares post-transaction. The purchase price sits 4.4% above current market price of $1.53 and represents an accumulation during a period of significant weakness: the stock is -30.1% from its 52-week high and has declined 21.5% over the past 30 days. Notably, Bach's prior open-market purchase at this same ticker on 2025-05-22 produced a 90-day return of +2.8%, reflecting a well-timed entry. The company remains unprofitable with net income of -$6,791,000.00 in the latest period and revenue of $0.00, providing limited fundamental support for conviction signals. The timing and scale of this transaction relative to recent price weakness warrant monitoring of whether this signals directional confidence or represents a tactical accumulation at depressed levels.

Director Robert L Van Nostrand buys 10,000 shares of SLS at $1.48; holdings double to 20.4K shares.

Director Robert L Van Nostrand purchased 10,000 shares at $1.48 on 2025-06-12, doubling his shareholding from 10,400 to 20,400 shares. The company reports $0.00 revenue in the latest quarter and net income of $-5,813,000.00, with annual revenue declining 100.0% year-over-year, indicating severe operational stress. While the stock has appreciated +9.9% over the past 30 days and +45.6% over 90 days from depressed levels, the director's open-market track record across all securities shows mixed results—his prior sells (4 total) averaged -3.2% returns over 30 days and -5.5% over 90 days, with 100.00% of those sales well-timed relative to subsequent stock declines. The purchase at $1.48 occurs $0.18 below current price of $1.66, within the 52-week range of $0.84–$1.94. This transaction represents a substantial increase in director exposure to a pre-revenue company in distress, warranting examination of whether operational recovery plans or capital allocation changes underpin the move.

Director Jane Wasman buys 20,000 SLS shares at $1.69; nearly triples holdings to 30,400 shares amid -100.0% revenue collapse.

Director Jane Wasman purchased 20,000 shares at $1.69 on 2025-05-30, increasing her holdings by 192.3% from 10,400 to 30,400 shares. The transaction occurs in a company with severe operational stress: latest quarterly revenue is $0.00, full-year net income was $-5,813,000.00, and annual revenue growth stands at -100.0%. The stock currently trades at $1.58, down 18.6% from its 52-week high of $1.94, placing the purchase price above the current level. This acquisition by a director during a period of zero revenue and substantial losses warrants investor scrutiny regarding both the operational challenges facing SELLAS and the director's confidence thesis in a turnaround.

SLS Director Kalin Katherine Bach purchased 20,000 shares at $1.80; holdings doubled to 41,000 shares amid -100.0% revenue decline.

Kalin Katherine Bach, a Director at SELLAS Life Sciences, purchased 20,000 shares at $1.80 on 2025-05-22, increasing her holdings by 95.2% to 41,000 shares. The transaction occurs in a company context marked by severe operational deterioration: latest-quarter revenue stands at $0.00 and annual revenue growth is -100.0%, while the company posted a net loss of $-5.8M over its most recent full fiscal year. The stock has recovered 36.4% over the past 30 days and 38.6% over 90 days from lower levels, trading at $1.76 against a 52-week high of $1.94. The substantial increase in her personal stake at a time of negative fundamentals and revenue collapse warrants investor scrutiny into the basis and timing of this accumulation decision.